NewAmsterdam Pharma Company N.V.
NAMSNewAmsterdam Pharma Company N.V. in brief
NewAmsterdam Pharma Company N.V. is a listed company in the Biotechnology industry, based in the Netherlands. Its market value was $2.6 B on 21 October 2026, which makes it the 5,496th largest listed company in the world and the 44th largest in the Netherlands on this site. In the year to December 2025 it had sales of $22 M and a net loss of $204 M. It employs about 100 people and Michael H. Davidson is its chief executive. Its shares trade under the symbol NAMS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About NewAmsterdam Pharma Company N.V.
We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol lowering therapy. In multiple Phase 3 trials, we have investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Additionally, we believe that CETP inhibition may also play a role in other indications by potentially mitigating the risk of developing diseases such as Alzheimer’s disease.
From the company's annual report filed with the US SEC: read the report
NewAmsterdam Pharma Company N.V. timeline
- 2022
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed NewAmsterdam Pharma Co N.V.Formerly NewAmsterdam Pharma Co B.V..
Events of NewAmsterdam Pharma Company N.V. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Netherlands: #52 (Dec 2022) · #59 (Jul 2023) · #53 (Jan 2024) · #2 (Mar 2026) · #45 (Aug 2026) · #45 (Oct 2026) · #44 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 99.4×
- Price / book
- 3.8×
- Free cash flow yield
- -5.7%
- Net margin (TTM)
- -790.2%
- Operating margin
- -1003.0%
- Return on equity
- -30.0%
- Liabilities / assets
- 11.2%
- Revenue growth
- -50.6%
- R&D / revenue
- 630.4%
- Revenue per employee
- $225 K
- Profit per employee
- $-2.0 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $23M | -50.6% | $-226M | $-204M | -905.9% |
| Dec 2024 | $46M | +223.3% | $-176M | $-242M | -530.3% |
| Dec 2023 | $14M | -86.3% | $-183M | $-177M | -1255.8% |
| Dec 2022 | $103M | — | $-4M | $-23M | -22.0% |
| Dec 2021 | — | — | $-35M | $-42M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-148M | $0M | $-148M | $-1.72 | — |
| Dec 2024 | $-159M | $1M | $-159M | $-2.56 | — |
| Dec 2023 | $-141M | $0M | $-141M | $-2.15 | — |
| Dec 2022 | $11M | $0M | $10M | $-1.19 | — |
| Dec 2021 | $-30M | $0M | $-30M | $-3.81 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (+5374.3% on a year earlier), net income $-17M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent report
- Sep 29, 20268-KCurrent reportOther events
- Sep 21, 20268-KCurrent reportOther events
- Aug 14, 20268-K/ACurrent report (amended)Directors or officers changed
- Aug 14, 20268-KCurrent reportDirectors or officers changed
- Aug 5, 20268-KCurrent reportResults of operations
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Jul 24, 20268-KCurrent reportOther events
- Jul 22, 20268-KCurrent reportDirectors or officers changed
- Jun 3, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 7, 20268-KCurrent reportResults of operations
Official filings of NewAmsterdam Pharma Company N.V. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $23 M
- Operating income
- $-226 M
- Net income
- $-204 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $769 M
- Total liabilities
- $86 M
- Total equity
- $683 M
As of December-2025
Top 100 institutional investors in NewAmsterdam Pharma Company N.V.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 18,988,902 | +900,000 (+4.98%) | 15.83% | $462 M | Nov 16, 2026 |
| 2 | Capital World Investors | 12,881,484 | +650,927 (+5.32%) | 10.74% | $313 M | Nov 12, 2026 |
| 3 | FMR LLC | 12,116,744 | +1,777,081 (+17.19%) | 10.10% | $295 M | Nov 10, 2026 |
| 4 | Ra Capital Management, L.P. | 9,550,191 | 0 (0.00%) | 7.96% | $232 M | Nov 16, 2026 |
| 5 | Janus Henderson Group Ltd. | 8,972,293 | — | 7.48% | $218 M | Nov 16, 2026 |
| 6 | Fcpm III Services B.V. | 8,490,353 | 0 (0.00%) | 7.08% | $206 M | Nov 16, 2026 |
| 7 | Deerfield Management Company, L.P. | 4,254,314 | -10,475 (-0.25%) | 3.55% | $103 M | Nov 16, 2026 |
| 8 | Bain Capital Life Sciences Investors, LLC | 3,806,559 | -7 (0.00%) | 3.17% | $93 M | Nov 16, 2026 |
| 9 | Orbis Allan Gray Ltd | 3,760,821 | +2,013,194 (+115.20%) | 3.14% | $91 M | Nov 16, 2026 |
| 10 | Duquesne Family Office LLC | 3,357,146 | +287,000 (+9.35%) | 2.80% | $82 M | Nov 16, 2026 |
| 11 | Viking Global Investors LP | 2,463,911 | -1,739,656 (-41.39%) | 2.05% | $60 M | Nov 16, 2026 |
| 12 | Medicxi Ventures Management (Jersey) Ltd | 2,182,339 | -26,300 (-1.19%) | 1.82% | $53 M | Nov 2, 2026 |
| 13 | Jennison Associates LLC | 2,077,595 | -24,691 (-1.17%) | 1.73% | $51 M | Nov 16, 2026 |
| 14 | Goldman Sachs Group Inc | 1,984,732 | +439,821 (+28.47%) | 1.65% | $48 M | Nov 16, 2026 |
| 15 | Maverick Capital LTD | 1,855,630 | -1,412,172 (-43.21%) | 1.55% | $45 M | Nov 16, 2026 |
| 16 | Capital International Investors | 1,842,170 | +118,675 (+6.89%) | 1.54% | $45 M | Nov 12, 2026 |
| 17 | Alliancebernstein L.P. | 1,440,944 | +181,004 (+14.37%) | 1.20% | $35 M | Nov 16, 2026 |
| 18 | Jpmorgan Chase & Co | 1,229,768 | +96,813 (+8.55%) | 1.03% | $30 M | Nov 12, 2026 |
| 19 | Aberdeen Group plc | 1,184,091 | +81,306 (+7.37%) | 0.99% | $29 M | Nov 10, 2026 |
| 20 | Price T Rowe Associates Inc /MD/ | 1,173,316 | +5,959 (+0.51%) | 0.98% | $29 M | Nov 16, 2026 |
| 21 | Two Sigma Investments, LP | 1,135,081 | +1,123,080 (+9358.22%) | 0.95% | $28 M | Nov 16, 2026 |
| 22 | BlackRock, Inc. | 1,040,638 | -23,112 (-2.17%) | 0.87% | $25 M | Nov 13, 2026 |
| 23 | Ameriprise Financial Inc | 956,961 | -296,588 (-23.66%) | 0.80% | $23 M | Nov 16, 2026 |
| 24 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 874,565 | +93,425 (+11.96%) | 0.73% | $21 M | Nov 13, 2026 |
| 25 | Castle Hook Partners LP | 873,367 | -497,638 (-36.30%) | 0.73% | $21 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Franklin Templeton Inc | 866,529 | -127,388 (-12.82%) | 0.72% | $21 M | Nov 12, 2026 |
| 27 | Polar Capital Holdings Plc | 866,109 | -858,409 (-49.78%) | 0.72% | $21 M | Nov 16, 2026 |
| 28 | American Century Companies Inc | 865,403 | +180,590 (+26.37%) | 0.72% | $21 M | Nov 12, 2026 |
| 29 | Morgan Stanley | 836,582 | +260,757 (+45.28%) | 0.70% | $20 M | Nov 13, 2026 |
| 30 | Millennium Management LLC | 784,158 | +282,544 (+56.33%) | 0.65% | $19 M | Nov 16, 2026 |
| 31 | Woodline Partners LP | 752,689 | +200 (+0.03%) | 0.63% | $18 M | Nov 16, 2026 |
| 32 | First Turn Management, LLC | 702,396 | +119,899 (+20.58%) | 0.59% | $17 M | Nov 16, 2026 |
| 33 | Nwi Management LP | 702,000 | 0 (0.00%) | 0.59% | $17 M | Nov 13, 2026 |
| 34 | Adage Capital Partners GP, L.L.C. | 700,000 | +150,000 (+27.27%) | 0.58% | $17 M | Nov 16, 2026 |
| 35 | Rock Springs Capital Management LP | 613,942 | +31,198 (+5.35%) | 0.51% | $15 M | Nov 16, 2026 |
| 36 | TimesSquare Capital Management, LLC | 573,186 | -222,976 (-28.01%) | 0.48% | $14 M | Nov 3, 2026 |
| 37 | Kennedy Capital Management LLC | 547,629 | +126,255 (+29.96%) | 0.46% | $13 M | Nov 13, 2026 |
| 38 | Artia Global Partners LP | 503,936 | 0 (0.00%) | 0.42% | $12 M | Nov 16, 2026 |
| 39 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 457,498 | New | 0.38% | $11 M | Nov 16, 2026 |
| 40 | Qube Research & Technologies Ltd | 373,272 | +326,182 (+692.68%) | 0.31% | $9 M | Nov 13, 2026 |
| 41 | Jump Financial, LLC | 357,521 | +213,009 (+147.40%) | 0.30% | $9 M | Nov 13, 2026 |
| 42 | Jane Street Group, LLC | 345,720 | -128,516 (-27.10%) | 0.29% | $8 M | Nov 12, 2026 |
| 43 | Bank of New York Mellon Corp | 337,981 | -15,317 (-4.34%) | 0.28% | $8 M | Nov 5, 2026 |
| 44 | Slate Path Capital LP | 319,000 | 0 (0.00%) | 0.27% | $8 M | Nov 16, 2026 |
| 45 | Mizuho Markets Cayman LP | 309,160 | +158,621 (+105.37%) | 0.26% | $8 M | Nov 9, 2026 |
| 46 | Victory Capital Management Inc | 308,835 | +136,172 (+78.87%) | 0.26% | $8 M | Nov 10, 2026 |
| 47 | Atle Fund Management AB | 303,824 | +54,976 (+22.09%) | 0.25% | $7 M | Nov 12, 2026 |
| 48 | Bank Of America Corp /de/ | 297,607 | -437,876 (-59.54%) | 0.25% | $7 M | Nov 16, 2026 |
| 49 | Susquehanna International Group, LLP | 286,860 | -467,467 (-61.97%) | 0.24% | $7 M | Nov 16, 2026 |
| 50 | Barclays PLC | 280,411 | +272,339 (+3373.87%) | 0.23% | $7 M | Nov 6, 2026 |
| 51 | Citadel Advisors LLC | 277,982 | -367,823 (-56.96%) | 0.23% | $7 M | Nov 16, 2026 |
| 52 | Affinity Asset Advisors, LLC | 275,000 | 0 (0.00%) | 0.23% | $7 M | Nov 13, 2026 |
| 53 | HRT Financial LP | 225,079 | -124,764 (-35.66%) | 0.19% | $5 M | Nov 13, 2026 |
| 54 | Eversept Partners, LP | 223,962 | -51,509 (-18.70%) | 0.19% | $5 M | Nov 16, 2026 |
| 55 | Wellington Management Group LLP | 206,477 | -12,272 (-5.61%) | 0.17% | $5 M | Nov 16, 2026 |
| 56 | Deutsche Bank AG\ | 204,457 | +4,526 (+2.26%) | 0.17% | $5 M | Nov 6, 2026 |
| 57 | Ghisallo Capital Management LLC | 200,000 | New | 0.17% | $5 M | Nov 16, 2026 |
| 58 | Vanguard Portfolio Management LLC | 196,630 | +14,956 (+8.23%) | 0.16% | $5 M | Nov 13, 2026 |
| 59 | Peregrine Capital Management LLC | 192,476 | +22,988 (+13.56%) | 0.16% | $5 M | Nov 9, 2026 |
| 60 | ArrowMark Colorado Holdings LLC | 184,214 | -27,629 (-13.04%) | 0.15% | $4 M | Nov 16, 2026 |
| 61 | BNP Paribas Financial Markets | 183,451 | +147,741 (+413.72%) | 0.15% | $4 M | Nov 12, 2026 |
| 62 | SEB Asset Management AB | 170,752 | -101,902 (-37.37%) | 0.14% | $4 M | Nov 4, 2026 |
| 63 | Nan Fung Group Holdings Ltd | 164,986 | New | 0.14% | $4 M | Nov 13, 2026 |
| 64 | Palo Alto Investors LP | 162,874 | +118,515 (+267.17%) | 0.14% | $4 M | Nov 16, 2026 |
| 65 | Ishara Investments LP | 160,000 | +123,100 (+333.60%) | 0.13% | $4 M | Nov 16, 2026 |
| 66 | Stempoint Capital LP | 159,044 | +81,455 (+104.98%) | 0.13% | $4 M | Nov 16, 2026 |
| 67 | Alps Advisors Inc | 158,398 | +40,253 (+34.07%) | 0.13% | $4 M | Nov 3, 2026 |
| 68 | TD Asset Management Inc | 148,400 | 0 (0.00%) | 0.12% | $4 M | Nov 13, 2026 |
| 69 | Kornitzer Capital Management Inc /KS | 141,711 | +1,778 (+1.27%) | 0.12% | $3 M | Nov 3, 2026 |
| 70 | DCF Advisers, LLC | 130,868 | -10,132 (-7.19%) | 0.11% | $3 M | Nov 4, 2026 |
| 71 | Swiss National Bank | 130,000 | +8,900 (+7.35%) | 0.11% | $3 M | Nov 12, 2026 |
| 72 | State Street Corp | 125,780 | +10,565 (+9.17%) | 0.10% | $3 M | Nov 12, 2026 |
| 73 | Geode Capital Management, LLC | 120,933 | +15,764 (+14.99%) | 0.10% | $3 M | Nov 6, 2026 |
| 74 | ADAR1 Capital Management, LLC | 118,623 | 0 (0.00%) | 0.10% | $3 M | Nov 16, 2026 |
| 75 | Man Group plc | 118,313 | +37,481 (+46.37%) | 0.10% | $3 M | Nov 16, 2026 |
| 76 | Balyasny Asset Management L.P. | 109,777 | New | 0.09% | $3 M | Nov 16, 2026 |
| 77 | Swedbank AB | 104,100 | 0 (0.00%) | 0.09% | $3 M | Oct 27, 2026 |
| 78 | Cormorant Asset Management, LP | 100,000 | -400,000 (-80.00%) | 0.08% | $2 M | Nov 16, 2026 |
| 79 | Jefferies Financial Group Inc. | 97,278 | -25,450 (-20.74%) | 0.08% | $2 M | Nov 5, 2026 |
| 80 | Manufacturers Life Insurance Company, The | 96,951 | +719 (+0.75%) | 0.08% | $2 M | Nov 13, 2026 |
| 81 | Northern Trust Corp | 91,617 | -2,354 (-2.51%) | 0.08% | $2 M | Nov 16, 2026 |
| 82 | Algert Global LLC | 87,590 | +6,250 (+7.68%) | 0.07% | $2 M | Nov 17, 2026 |
| 83 | Tudor Investment Corp Et Al | 85,007 | +5,547 (+6.98%) | 0.07% | $2 M | Nov 16, 2026 |
| 84 | AQR Capital Management LLC | 78,096 | +55,405 (+244.17%) | 0.07% | $2 M | Nov 16, 2026 |
| 85 | Moody Aldrich Partners LLC | 77,941 | -12,676 (-13.99%) | 0.07% | $2 M | Oct 27, 2026 |
| 86 | Verition Fund Management LLC | 77,145 | New | 0.06% | $2 M | Nov 13, 2026 |
| 87 | California State Teachers Retirement System | 74,900 | +7,482 (+11.10%) | 0.06% | $2 M | Nov 13, 2026 |
| 88 | UBS Group AG | 71,401 | -272,664 (-79.25%) | 0.06% | $2 M | Nov 10, 2026 |
| 89 | WINTON GROUP Ltd | 70,765 | New | 0.06% | $2 M | Nov 12, 2026 |
| 90 | Pavaki Capital Management LLC | 66,600 | 0 (0.00%) | 0.06% | $2 M | Oct 26, 2026 |
| 91 | Nomura Asset Management International Inc. | 64,973 | New | 0.05% | $2 M | Nov 16, 2026 |
| 92 | Citigroup Inc | 56,590 | +48,564 (+605.08%) | 0.05% | $1 M | Nov 4, 2026 |
| 93 | Gsa Capital Partners LLP | 56,108 | New | 0.05% | $1 M | Nov 16, 2026 |
| 94 | Knights of Columbus Asset Advisors LLC | 56,070 | +12,270 (+28.01%) | 0.05% | $1 M | Nov 5, 2026 |
| 95 | Squarepoint Ops LLC | 50,906 | -41,120 (-44.68%) | 0.04% | $1 M | Nov 9, 2026 |
| 96 | VANGUARD ASSET MANAGEMENT, Ltd | 48,274 | +5,852 (+13.79%) | 0.04% | $1 M | Nov 13, 2026 |
| 97 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 44,241 | -19,057 (-30.11%) | 0.04% | $1 M | Nov 16, 2026 |
| 98 | SEI Investments Co | 43,656 | +2,788 (+6.82%) | 0.04% | $1 M | Nov 10, 2026 |
| 99 | Legal & General Group Plc | 43,309 | +3,966 (+10.08%) | 0.04% | $1 M | Nov 16, 2026 |
| 100 | Lord, Abbett & Co. LLC | 42,000 | -264,560 (-86.30%) | 0.04% | $1 M | Nov 13, 2026 |
Superinvestors holding NewAmsterdam Pharma Company N.V.
2 of the well-known investors value.today follows, from their newest Form 13F.
- Duquesne Family Office · Stanley Druckenmiller$82 M+287,000 · Sep 30, 2026
- Viking Global Investors · Andreas Halvorsen$60 M−1.7 M · Sep 30, 2026
Mutual funds holding NewAmsterdam Pharma Company N.V.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc | 9.27 M | $314 M | 7.7% | 0.33% | +10% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 2.01 M | $68 M | 1.7% | 0.03% | +38% | May 31, 2026 |
| 🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC | 1.68 M | $57 M | 1.4% | 0.03% | +33% | Jun 30, 2026 |
| 🇺🇸 New Economy FundCapital Research and Management Company | 957,477 | $32 M | 0.80% | 0.06% | no change | May 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 912,500 | $31 M | 0.76% | 0.26% | new | Jun 30, 2026 |
| 🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC | 690,000 | $23 M | 0.58% | 0.40% | +3.0% | May 31, 2026 |
| 🇺🇸 Capital Group U.S. Small and Mid Cap ETFCapital Research and Management Company | 608,660 | $20 M | 0.51% | 0.73% | +197% | May 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 566,140 | $19 M | 0.47% | 0.21% | +5.3% | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC | 534,102 | $18 M | 0.45% | 1.3% | no change | May 29, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 523,700 | $18 M | 0.44% | 0.33% | −6.9% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc. | 503,537 | $17 M | 0.42% | 0.65% | +12% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 476,416 | $16 M | 0.40% | 1.2% | +39% | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Growth FundColumbia Funds Series Trust I | 445,889 | $15 M | 0.37% | 0.41% | new | May 31, 2026 |
| 🇺🇸 Small Cap Growth FundAmerican Century Investment Management, Inc. | 524,241 | $15 M | 0.44% | 0.26% | +21% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 504,110 | $14 M | 0.42% | 0.16% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 471,600 | $13 M | 0.39% | 0.18% | +16% | Jul 31, 2026 |
| 🇺🇸 abrdn World Healthcare Fundabrdn Inc. | 382,193 | $13 M | 0.32% | 2.3% | +13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 448,000 | $12 M | 0.37% | 0.57% | −24% | Jul 31, 2026 |
| 🇺🇸 Columbia Acorn FundColumbia Management Investment Advisers, LLC | 363,308 | $12 M | 0.30% | 0.44% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC | 361,718 | $12 M | 0.30% | 0.03% | +32% | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 420,000 | $12 M | 0.35% | 0.37% | +20% | Jul 31, 2026 |
| 🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P. | 292,628 | $10 M | 0.24% | 0.32% | −4.7% | Jun 30, 2026 |
| 🇺🇸 AB Discovery Growth Fund, Inc.AllianceBernstein L.P. | 289,630 | $10 M | 0.24% | 0.34% | −0.5% | Jun 30, 2026 |
| 🇺🇸 Harbor Small Cap Growth FundHarbor Capital Advisors, Inc. | 344,443 | $10 M | 0.29% | 0.36% | −27% | Jul 31, 2026 |
| 🇸🇪 SEB LäkemedelsfondSEB Funds AB | 272,654 | $9 M | 0.23% | 0.51% | no change | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World FundCapital Research and Management Company | 257,315 | $9 M | 0.21% | 0.34% | new | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 244,176 | $8 M | 0.20% | 1.2% | +55% | Jun 30, 2026 |
| 🇺🇸 Fidelity FundFidelity Management & Research Company LLC | 243,800 | $8 M | 0.20% | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc. | 292,360 | $8 M | 0.24% | 0.33% | −1.5% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 270,700 | $8 M | 0.23% | 0.16% | −5.2% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 250,980 | $7 M | 0.21% | 0.15% | no change | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 174,388 | $6 M | 0.15% | 0.28% | +6.0% | Jun 30, 2026 |
| 🇺🇸 Victory Pioneer Disciplined Growth FundVictory Capital Management Inc. | 172,663 | $6 M | 0.14% | 0.25% | new | May 31, 2026 |
| 🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I | 162,575 | $6 M | 0.14% | 0.64% | −8.9% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc. | 162,503 | $6 M | 0.14% | 0.33% | +12% | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 187,726 | $5 M | 0.16% | 0.45% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Discovery FundFidelity Management & Research Company LLC | 183,400 | $5 M | 0.15% | 0.22% | +23% | Jul 31, 2026 |
| 🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC | 140,000 | $5 M | 0.12% | 0.41% | +22% | Jun 30, 2026 |
| 🇺🇸 Buffalo Mid Cap Discovery FundKornitzer Capital Management, Inc. | 138,948 | $5 M | 0.12% | 1.4% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 135,312 | $5 M | 0.11% | 0.02% | −0.2% | May 31, 2026 |
| 🇸🇪 HealthInvest Small & Mid Cap HealthcareAtle Fund Management AB | 131,396 | $4 M | 0.11% | 3.5% | +48% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Discovery FundFidelity Management & Research Company LLC | 157,200 | $4 M | 0.13% | 0.22% | +20% | Jul 31, 2026 |
| 🇺🇸 Putnam Global Health Care FundPutnam Investment Management, LLC | 120,500 | $4 M | 0.10% | 0.28% | +5.8% | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Small Cap FundFidelity Management & Research Company LLC | 119,300 | $4 M | 0.10% | 0.17% | no change | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 118,514 | $4 M | 0.10% | 2.5% | +17% | May 31, 2026 |
| 🇸🇪 HealthInvest Sustainable HealthcareAtle Fund Management AB | 117,452 | $4 M | 0.10% | 1.1% | +41% | Jun 30, 2026 |
| 🇺🇸 American Funds U.S. Small & Mid Cap Equity FundAmerican Funds U.S. Small & Mid Cap Equity Fund | 116,333 | $4 M | 0.10% | 0.57% | +238% | May 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company | 140,000 | $4 M | 0.12% | 0.08% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 110,693 | $4 M | 0.09% | 0.17% | +20% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC | 134,200 | $4 M | 0.11% | 0.24% | +24% | Jul 31, 2026 |
| 🇸🇪 Swedbank Robur HealthcareSwedbank Robur Fonder AB | 104,100 | $4 M | 0.09% | 0.23% | +3.2% | Jun 30, 2026 |
| 🇸🇪 Handelsbanken Hälsovård TemaHandelsbanken Fonder AB | 100,000 | $3 M | 0.08% | 0.14% | −75% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P. | 91,871 | $3 M | 0.08% | 0.36% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 111,035 | $3 M | 0.09% | 0.12% | +27% | Jul 31, 2026 |
| 🇺🇸 Eaton Vance Worldwide Health Sciences FundEaton Vance Management | 81,652 | $3 M | 0.07% | 0.36% | no change | May 31, 2026 |
| 🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC | 79,983 | $3 M | 0.07% | 0.23% | −8.9% | May 29, 2026 |
| 🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC | 94,531 | $3 M | 0.08% | 0.20% | +128% | Jul 31, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Acorn FundColumbia Management Investment Advisers, LLC | 69,887 | $2 M | 0.06% | 0.44% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 70,289 | $2 M | 0.06% | <0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 Allspring Small Company Growth FundAllspring Funds Management, LLC | 78,861 | $2 M | 0.07% | 0.43% | −1.3% | Jul 31, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 60,383 | $2 M | 0.05% | 0.20% | +15% | Jun 30, 2026 |
| 🇺🇸 Optimum Small-Mid Cap Growth FundDelaware Management Company | 58,613 | $2 M | 0.05% | 0.21% | −3.7% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 57,600 | $2 M | 0.05% | 0.26% | new | Jun 30, 2026 |
| 🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC | 55,796 | $2 M | 0.05% | 0.13% | +5.9% | Jun 30, 2026 |
| 🇺🇸 Lord Abbett Micro-Cap Growth FundLord, Abbett & Co. LLC | 65,889 | $2 M | 0.05% | 0.86% | +68% | Jul 31, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 53,374 | $2 M | 0.04% | 0.66% | no change | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 53,618 | $2 M | 0.04% | 0.14% | −20% | May 31, 2026 |
| 🇺🇸 Lord Abbett International Opportunities FundLord, Abbett & Co. LLC | 60,000 | $2 M | 0.05% | 0.50% | +43% | Jul 31, 2026 |
| 🇺🇸 Mercer US Small/Mid Cap Equity FundMercer Investments LLC | 45,790 | $2 M | 0.04% | 0.08% | −32% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 45,506 | $2 M | 0.04% | <0.01% | −55% | May 31, 2026 |
| 🇺🇸 AMG TimesSquare Small Cap Growth FundAMG Funds LLC | 42,974 | $1 M | 0.04% | 1.3% | — | Jun 30, 2026 |
| 🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC | 49,856 | $1 M | 0.04% | 0.09% | +17% | Jul 31, 2026 |
| 🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc. | 40,364 | $1 M | 0.03% | 0.48% | +164% | Jun 30, 2026 |
| 🇺🇸 Empower Small Cap Growth FundEmpower Capital Management, LLC | 39,647 | $1 M | 0.03% | 0.52% | +0.7% | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 46,400 | $1 M | 0.04% | 0.05% | −51% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 34,423 | $1 M | 0.03% | 0.01% | +1.7% | May 31, 2026 |
| 🇺🇸 Knights of Columbus Small Cap Equity FundKnights of Columbus Asset Advisors LLC | 40,016 | $1 M | 0.03% | 0.53% | +22% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 32,536 | $1 M | 0.03% | 0.50% | +73% | Jun 30, 2026 |
| 🇺🇸 iShares ESG Aware MSCI USA Small-Cap ETFBlackRock Fund Advisors | 32,510 | $1 M | 0.03% | 0.05% | +15% | May 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 31,311 | $1 M | 0.03% | 0.22% | +387% | Jun 30, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Small Company Growth FundColumbia Management Investment Advisers, LLC | 30,325 | $1 M | 0.03% | 0.39% | +109% | Jun 30, 2026 |
| 🇺🇸 Small Cap Growth FundThe Variable Annuity Life Insurance Company | 28,262 | $1 M | 0.02% | 0.18% | −5.9% | May 31, 2026 |
| 🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC | 26,479 | $1 M | 0.02% | 0.03% | −68% | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 28,680 | $1 M | 0.02% | 0.02% | +35% | Jul 31, 2026 |
| 🇺🇸 Franklin Alternative Strategies FundFranklin Advisers, Inc. | 23,134 | $1 M | 0.02% | 0.13% | — | May 29, 2026 |
| 🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB | 22,400 | $1 M | 0.02% | 0.03% | +19% | Jun 30, 2026 |
| 🇺🇸 Catholic Responsible Investments Small-Mid Cap Equity FundChristian Brothers Investment Services, Inc. | 25,180 | $1 M | 0.02% | 0.12% | new | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 20,200 | $1 M | 0.02% | 0.27% | new | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 19,307 | $1 M | 0.02% | 0.09% | −1.7% | May 31, 2026 |
| 🇺🇸 U.S. Small and Mid Cap Equity FundCapital Research and Management Company | 18,143 | $1 M | 0.02% | 0.56% | — | Jun 30, 2026 |
| 🇺🇸 AVIP AB Small Cap PortfolioCONSTELLATION INVESTMENTS INC | 15,720 | $1 M | 0.01% | 0.17% | −2.3% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 19,093 | $1 M | 0.02% | 0.05% | +29% | Jul 31, 2026 |
| 🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC | 15,500 | $1 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BNY Mellon Small Cap Multi-Strategy FundBNY Mellon Investment Adviser, Inc. | 15,063 | $1 M | 0.01% | 0.39% | −13% | May 31, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 14,300 | $0 M | 0.01% | 0.27% | new | Jun 30, 2026 |
| 🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P. | 16,480 | $0 M | 0.01% | 0.13% | — | Apr 30, 2026 |
| 🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC | 13,400 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Putnam VT Global Health Care FundPutnam Investment Management, LLC | 11,600 | $0 M | <0.01% | 0.27% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 11,035 | $0 M | <0.01% | 0.09% | new | Jun 30, 2026 |
| 🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC | 9,903 | $0 M | <0.01% | 0.14% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at NewAmsterdam Pharma Company N.V.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Option exercise10b5-1 plan · indirect | +50,246 | — | — | 119,548 | Form 4 |
| filed | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Sell10b5-1 plan · indirect | -50,246 | $25.03 | $1.3 M | 69,302 | Form 4 |
| filed | Michael H. DavidsonChief Executive Officer, Director | Buy | +10,000 | $22.65 | $227 K | 792,923 | Form 4 |
| filed | John W. SmitherDirector | Sell | -1,600 | $25.32 | $41 K | 8,760 | Form 4 |
| filed | Robert William GunningVice President, Controller | Grant or award | +3,200 | — | — | 3,200 | Form 4 |
| filed | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Option exercise10b5-1 plan · indirect | +125,000 | — | — | 194,302 | Form 4 |
| filed | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Sell10b5-1 plan · indirect | -125,000 | $26.91 | $3.4 M | 69,302 | Form 4 |
| filed | Louise Frederika KooijChief Accounting Officer | Option exercise10b5-1 plan | +25,000 | $11.90 | $298 K | 49,353 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: NewAmsterdam Pharma Company N.V.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2024-12-10 11:55 UTC, code T3, resumed 12:30 UTC
- 2024-11-20 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 2,466 shares at $21.50
- : 1,038 shares at $20.62
- : 442 shares at $22.27
- : 36,694 shares at $24.16
- : 1,953 shares at $24.32
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
NewAmsterdam Pharma Company N.V. scorecard#
Passes 2 of the 16 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 21, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.8×Price to book 3.8× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median99.4×Price to sales 99.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-5.7%Free cash flow is -5.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 4
- ✗Revenue grew in the newest year-50.6%Revenue down 50.6% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-39.7%-39.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-39.7%-39.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.72 vs -2.56Diluted EPS -1.72 in fiscal 2025 against -2.56 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$204 MNet income -$204 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-28.3%-28.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities7.9×Current ratio 7.88 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone16.61Z-score 16.61 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year25.5%Diluted shares up 25.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from NewAmsterdam Pharma Company N.V.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Net margin | -905.9% | -68.9% | |
| Return on equity | -28.3% | -61.0% | |
| Revenue growth, 3 years a year | -39.7% | 12.9% | |
| Revenue growth | -50.6% | 15.8% | |
| Free cash flow margin | -657.9% | -61.5% |
2of 7on the Piotroski tests of financial strength
- Revenue fell 50.6% against the year before.
- Net loss of $204 million, the 5th loss-making year in a row.
- Free cash flow was negative: -$148 million.
- The share count rose 25.5% in the year.
NewAmsterdam Pharma Company N.V.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 · USD | FY 2024to Dec 31, 2024 · USD | FY 2023to Dec 31, 2023 · USD | FY 2022to Dec 31, 2022 · EUR | FY 2021to Dec 31, 2021 · EUR | FY 2020to Dec 31, 2020 · EUR |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 23−50.6%100% | 46+223%100% | 14—100% | 98—100% | — | — | |
| Research and development | 142−6.3%630% | 151−5.0%332% | 159—1131% | 82+228%84.3% | 25+519%— | 4.0—— | |
| Selling, general and administrative | 106+51.0%473% | 70+87.2%155% | 38—267% | 22+363%22.8% | 4.8+247%— | 1.4—— | |
| General and administrative | 15+6.5%68.3% | 14−11.5%31.7% | 16—116% | — | — | — | |
| Operating expenses | 248+11.9%1103% | 222+12.6%487% | 197—1399% | — | — | — | |
| Total costs and expenses | — | — | — | 165+453%169% | 30+450%— | 5.4—— | |
| Operating income | −226—−1003% | −176—−387% | −183—−1299% | −68—−69.3% | −30—— | −5.4—— | |
| Interest and finance income | 28+63.5%123% | 17+49.6%37.0% | 11—80.1% | 0.0+22.2%0.0% | 0.0—— | — | |
| Interest expense and finance costs | — | — | — | 0.3+25.5%0.3% | 0.2−37.2%— | 0.3—— | |
| Income before tax | −204—−906% | −242—−530% | −177—−1256% | −78—−80.1% | −29—— | −5.7—— | |
| Income tax | — | −0.0−104%−0.0% | 0.0—0.2% | — | — | — | |
| Net income including minority interests | −204—−906% | −242—−530% | −177—−1256% | −78—−80.1% | −29—— | −5.7—— | |
| Net income attributable to shareholders | −204—−906% | −242—−530% | −177—−1256% | −78r−0.1—−80.1% | −29r−0.0—— | −5.7r−0.0—— | |
| Earnings per share, basic | -1.72—— | -2.56—— | -2.15—— | -1.97r-0.96—— | -1.21r-1.19—— | -0.62r-0.54—— | |
| Earnings per share, diluted | -1.72—— | -2.56—— | -2.15—— | -1.97r-0.96—— | -1.21r-1.19—— | -0.62r-0.54—— | |
| Shares, weighted average (basic) | 118+25.5%— | 94+14.8%— | 82—— | 19r82+72.8%— | 11+19.2%— | 9.2r11—— | |
| Shares, weighted average (diluted) | 118+25.5%— | 94+14.8%— | 82—— | 19+72.8%— | 11+154%— | 4.3r5.0—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 490−36.5%63.7% | 772+127%89.3% | 340—98.1% | 439+726%82.5% | 53+575%88.8% | 7.9—— | |
| Short-term investments | 146+134%19.0% | 62—7.2% | — | — | — | — | |
| Other current assets | 38+57.1%5.0% | 24+283%2.8% | 6.3—1.8% | — | — | — | |
| Current assets | 676−21.7%87.8% | 863+149%99.9% | 347—99.9% | 448+661%84.3% | 59—98.5% | — | |
| Property, plant and equipment | 0.4+58.3%0.0% | 0.2+426%0.0% | 0.0—0.0% | 0.1−24.2%0.0% | 0.2+1483%0.3% | 0.0—— | |
| Right-of-use (leased) assets | 0.2−57.1%0.0% | 0.4+684%0.0% | 0.1—0.0% | 0.1−30.2%0.0% | 0.2—0.3% | — | |
| Other intangible assets | — | — | — | 83—15.6% | — | — | |
| Non-current assets | — | — | — | 83+9091%15.7% | 0.9—1.5% | — | |
| Total assets | 769−11.0%100% | 865+149%100% | 347—100% | 532+789%100% | 60—100% | — | |
| Accounts payable | 9.0+89.1%1.2% | 4.7−72.0%0.5% | 17—4.9% | 19+88.3%3.5% | 9.8—16.4% | — | |
| Current liabilities | 86−19.8%11.2% | 107+114%12.4% | 50—14.4% | 35+259%6.7% | 9.9—16.5% | — | |
| Lease liabilities (non-current) | 0.1−67.3%0.0% | 0.2—0.0% | — | 0.1−49.5%0.0% | 0.1—0.2% | — | |
| Non-current liabilities | — | — | — | 12+10351%2.2% | 0.1—0.2% | — | |
| Total liabilities | 86−19.9%11.2% | 107+82.5%12.4% | 59—16.9% | — | — | — | |
| Retained earnings | −762—−99.1% | −559—−64.6% | −317—−91.3% | — | — | — | |
| Shareholders' equity | 683−9.8%88.8% | 758+163%87.6% | 288—83.1% | — | — | — | |
| Total equity | — | — | — | 485+873%91.1% | 50—83.3% | −3.6—— | |
| Total liabilities and equity | 769−11.0%100% | 865+149%100% | 347—100% | 532+789%100% | 60—100% | — | |
| Shares outstanding | 114+5.9%— | 108r108+31.0%— | 82—— | 82+620%— | 11+127%— | 5.0—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.2+94.7%1.0% | 0.1+131%0.2% | 0.0—0.3% | 0.1+414%0.1% | 0.0+1300%— | 0.0—— | |
| Share-based compensation | 59+76.8%264% | 34+36.8%73.8% | 25—174% | 3.9+274%4.0% | 1.0—— | — | |
| Cash from operating activities | −148—−657% | −159—−348% | −141—−1002% | 8.0—8.2% | −25—— | −6.0—— | |
| Capital expenditure | −0.2—−1.1% | −0.7—−1.5% | −0.0—−0.2% | −0.0—−0.0% | −0.0—— | −0.0—— | |
| Cash from investing activities | −175—−777% | −63—−138% | −0.0—−0.2% | 0.7—0.7% | −0.0—— | −0.0—— | |
| Debt issued | — | — | — | — | — | 11—— | |
| Debt repaid | — | — | — | −0.7—−0.7% | — | — | |
| Cash from financing activities | 30−95.5%131% | 660+7300%1447% | 8.9—63.3% | 375+444%385% | 69+509%— | 11—— | |
| Exchange-rate effect on cash | — | — | — | 1.6+9.9%1.6% | 1.4+5838%— | 0.0—— | |
| Report | 10-K | 10-K | 10-K | 20-F/A | 20-F/A | 20-F/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 26−26.4%100% | 19+5407%100% | 3.7−80.7%100% | 3.0+2.1%100% | 0.0*−99.7%100% | 0.3−98.8%100% | 19+740%100% | 3.0+113%100% | 13*—100% | 29—100% | 2.3—100% | 1.4—100% | |
| Research and development | 158+14.1%608% | 39+27.1%205% | 42+51.5%1126% | 38−15.1%1250% | 39*+10.6%120606% | 31−13.3%8900% | 28−28.3%144% | 45+5.5%1503% | 35*—273% | 36—123% | 38—1684% | 42—3029% | |
| Selling, general and administrative | 102+1.7%392% | 24−2.1%125% | 27−1.4%727% | 23−13.6%771% | 27r27*+29.9%85678% | 25r25+33.2%7046% | 27+65.5%142% | 27+87.9%912% | 21*—165% | 18—63.2% | 16—723% | 14—1032% | |
| General and administrative | 16+3.3%59.9% | 5.0+79.7%25.8% | 3.9−10.1%105% | 2.7−37.2%89.3% | 4.0*+9.4%12463% | 2.8−27.0%792% | 4.3+19.7%22.5% | 4.3+26.4%145% | 3.6*—28.5% | 3.8—13.0% | 3.6—158% | 3.4—244% | |
| Operating expenses | 259+8.9%1000% | 63+14.2%331% | 69+25.2%1853% | 61−14.5%2022% | 66r66*+17.9%206284% | 55r55+2.5%15946% | 55−0.1%286% | 72+26.4%2414% | 56*—438% | 54—186% | 55—2407% | 57—4060% | |
| Operating income | −233—−900% | −44—−231% | −65—−1753% | −58—−1922% | −66r−66*—−206184% | −55r−55—−15846% | −36—−186% | −69—−2314% | −43*—−338% | −25—−85.9% | −53—−2307% | −55—−3960% | |
| Interest and finance income | 23−9.7%89.1% | 5.2−22.7%27.1% | 5.8−17.6%157% | 5.7−23.1%186% | 6.5*+44.3%20228% | 6.7+51.1%1929% | 7.1+44.9%36.9% | 7.4+138%247% | 4.5*—35.1% | 4.4—15.3% | 4.9—214% | 3.1—220% | |
| Income before tax | −204—−785% | −16—−84.4% | −64—−1733% | −48—−1593% | −75*—−234134% | −72—−20691% | −17—−90.7% | −40—−1327% | −92*—−722% | −17—−57.2% | −39—−1712% | −94—−6693% | |
| Income tax | — | 1.2—6.3% | — | — | — | — | — | — | 0*—0.0% | −0.0—−0.0% | — | — | |
| Net income including minority interests | −205—−790% | −17*—−90.7% | −64*—−1733% | −48—−1593% | −75*—−234134% | −72*—−20691% | −17*—−90.7% | −40—−1327% | −92*—−722% | −17*—−57.2% | −39*—−1712% | −94—−6693% | |
| Net income attributable to shareholders | −205—−790% | −17—−90.7% | −64—−1733% | −48—−1593% | −75*—−234134% | −72—−20691% | −17—−90.7% | −40—−1327% | −92*—−722% | −17—−57.2% | −39—−1712% | −94—−6693% | |
| Earnings per share, basic | — | -0.14—— | -0.52—— | -0.40—— | — | -0.61—— | -0.15—— | -0.34—— | — | -0.18—— | -0.41—— | -1.06—— | |
| Earnings per share, diluted | — | -0.14—— | -0.52—— | -0.40—— | — | -0.61—— | -0.15—— | -0.34—— | — | -0.18—— | -0.41—— | -1.06—— | |
| Shares, weighted average (basic) | 124+4.3%— | 124+4.3%— | 123+4.1%— | 122+4.8%— | — | 119+25.6%— | 119+25.2%— | 116+31.4%— | — | 95—— | 95—— | 88—— | |
| Shares, weighted average (diluted) | 124+4.3%— | 124+4.3%— | 123+4.1%— | 122+4.8%— | — | 119+25.6%— | 119+25.2%— | 116+31.4%— | — | 95—— | 95—— | 88—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 423—61.5% | 423−21.4%61.5% | 424−24.8%60.2% | 458−38.9%62.5% | 490−36.5%63.7% | 538+27.4%68.5% | 564+30.9%69.2% | 748+55.5%91.4% | 772—89.3% | 423—96.3% | 431—96.4% | 481—98.5% | |
| Short-term investments | 205—29.8% | 205+24.7%29.8% | 210+19.6%29.8% | 178+197%24.4% | 146+134%19.0% | 165—20.9% | 175—21.5% | 60—7.3% | 62—7.2% | — | — | — | |
| Other current assets | 42—6.2% | 42+51.1%6.2% | 24−21.8%3.4% | 21+133%2.8% | 38+57.1%5.0% | 28+85.4%3.6% | 31+110%3.8% | 8.8+32.2%1.1% | 24—2.8% | 15—3.4% | 15—3.3% | 6.7—1.4% | |
| Current assets | 672—97.7% | 672−8.2%97.7% | 659−14.4%93.6% | 658−19.5%89.8% | 676−21.7%87.8% | 732+67.2%93.1% | 770+72.9%94.4% | 817+67.5%99.9% | 863—99.9% | 438—99.7% | 445—99.7% | 488—99.9% | |
| Property, plant and equipment | 0.6—0.1% | 0.6+71.5%0.1% | 0.4+31.7%0.1% | 0.4+59.2%0.1% | 0.4+58.3%0.0% | 0.3+39.8%0.0% | 0.3+33.3%0.0% | 0.2+136%0.0% | 0.2—0.0% | 0.2—0.1% | 0.2—0.1% | 0.1—0.0% | |
| Right-of-use (leased) assets | 0.1—0.0% | 0.1−69.5%0.0% | 0.1−73.4%0.0% | 0.0−94.3%0.0% | 0.2−57.1%0.0% | 0.2−50.1%0.0% | 0.3−44.4%0.0% | 0.4+871%0.0% | 0.4—0.0% | 0.5—0.1% | 0.6—0.1% | 0.0—0.0% | |
| Total assets | 688—100% | 688−12.5%100% | 704−13.6%100% | 733−10.5%100% | 769−11.0%100% | 786+79.1%100% | 815+82.5%100% | 818+67.5%100% | 865—100% | 439—100% | 447—100% | 488—100% | |
| Accounts payable | 4.6—0.7% | 4.6+27.4%0.7% | 5.4−8.0%0.8% | 8.1+32.9%1.1% | 9.0+89.1%1.2% | 3.6−48.4%0.5% | 5.9+11.8%0.7% | 6.1−28.7%0.7% | 4.7—0.5% | 7.0—1.6% | 5.3—1.2% | 8.5—1.7% | |
| Current liabilities | 57—8.3% | 57−1.9%8.3% | 73+99.9%10.4% | 67+64.8%9.2% | 86−19.8%11.2% | 58+41.2%7.4% | 37−19.4%4.5% | 41−31.5%5.0% | 107—12.4% | 41—9.4% | 45—10.1% | 60—12.2% | |
| Lease liabilities (non-current) | 0.0—0.0% | 0.0−42.4%0.0% | 0.1−45.6%0.0% | — | 0.1−67.3%0.0% | 0.1−68.0%0.0% | 0.1−68.6%0.0% | 0.1—0.0% | 0.2—0.0% | 0.3—0.1% | 0.3—0.1% | — | |
| Total liabilities | 57—8.3% | 57−2.0%8.3% | 73+99.5%10.4% | 67+64.2%9.2% | 86−19.9%11.2% | 58−3.3%7.4% | 37−38.2%4.5% | 41−46.5%5.0% | 107—12.4% | 60—13.7% | 59—13.3% | 77—15.7% | |
| Retained earnings | −892—−130% | −892—−130% | −875—−124% | −811—−111% | −762—−99.1% | −687—−87.4% | −615—−75.5% | −598—−73.1% | −559—−64.6% | −466—−106% | −450—−101% | −411—−84.1% | |
| Shareholders' equity | 631—91.7% | 631−13.4%91.7% | 631−18.9%89.6% | 665−14.4%90.8% | 683−9.8%88.8% | 728+92.2%92.6% | 778+101%95.5% | 777+88.8%95.0% | 758—87.6% | 379—86.3% | 387—86.7% | 412—84.3% | |
| Total liabilities and equity | 688—100% | 688−12.5%100% | 704−13.6%100% | 733−10.5%100% | 769−11.0%100% | 786+79.1%100% | 815+82.5%100% | 818+67.5%100% | 865—100% | 439—100% | 447—100% | 488—100% | |
| Shares outstanding | 120—— | 120+5.9%— | 118+4.6%— | 117+4.0%— | 114+5.9%— | 113+22.8%— | 113+25.0%— | 112+25.0%— | 108r108—— | 92—— | 90—— | 90—— | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | 0.3−17.3%1.1% | 0.1*−46.4%0.3% | 0.1−16.8%2.4% | 0.1+19.2%2.0% | 0.1*+15.7%184% | 0.1+40.4%35.9% | 0.1+62.1%0.6% | 0.1+247%1.7% | 0.1*—0.4% | 0.1—0.3% | 0.1—2.9% | 0.0—1.1% | |
| Share-based compensation | 63+14.8%243% | 13−16.6%65.3% | 18+21.1%497% | 18+18.3%592% | 14*+48.9%43822% | 15+87.7%4313% | 15+83.1%79.3% | 15+92.1%511% | 9.4*—73.7% | 8.0—27.5% | 8.3—364% | 7.9—565% | |
| Cash from operating activities | −150—−580% | −40*—−208% | −39*—−1060% | −31—−1007% | −41*—−127734% | −33*—−9416% | −38*—−197% | −36—−1225% | −37*—−293% | −13*—−42.9% | −54*—−2369% | −55—−3897% | |
| Capital expenditure | −0.4—−1.5% | −0.2*—−0.9% | −0.1*—−2.2% | −0.0—−1.3% | −0.1*—−313% | −0.0*—−12.1% | −0.1*—−0.5% | −0.0—−0.5% | −0.0*—−0.0% | −0.1*—−0.3% | −0.2*—−9.2% | −0.4—−27.5% | |
| Cash from investing activities | −3.7—−14.3% | 34*+1245%176% | −4.8*—−129% | −12−503%−379% | −21*—−66066% | 2.5*—720% | −159*—−831% | 2.9—95.9% | −62*—−487% | −0.1*—−0.3% | −0.2*—−9.2% | −0.4—−27.5% | |
| Cash from financing activities | 41−91.3%159% | 5.5*−7.5%28.4% | 11*+222%298% | 11+69.7%364% | 14*−97.0%42763% | 5.9*+10059%1693% | 3.4*−26.5%17.9% | 6.5−96.7%219% | 457*—3575% | 0.1*—0.2% | 4.7*—204% | 198—14146% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where NewAmsterdam Pharma Company N.V. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇳🇱 Netherlands | Headquarters1 office1 subsidiary | — |
| 🇺🇸 USA | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at NewAmsterdam Pharma Company N.V.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Michael Davidson, M.D. | $13.6 M | $30.5 M | $4.3 M | $322 (peers $135) |
| 2024Michael Davidson, M.D. | $6.5 M | $49.5 M | $2.6 M | $236 (peers $104) |
| 2023Michael Davidson, M.D. | $5.8 M | $4.7 M | $3.3 M | $102 (peers $105) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at NewAmsterdam Pharma Company N.V.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 2 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026
Acquisitions and funding#
1 acquisitions
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Holding B.V. and NewAmsterdam Pharma Investment Corporation | Jul 2022 | — | — | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Discuss NewAmsterdam Pharma Company N.V.#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 117 funds hold $999 millionautomatic update · Jul 31, 2026
117 mutual funds in 2 countries hold shares of NewAmsterdam Pharma Company N.V. worth $999 million, about 25.4% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 64 funds added shares and 39 sold; on balance they bought $37 million. Share splits are not counted as trading.
How NewAmsterdam Pharma Company N.V. compares in Biotechnology
- Market cap$2.6 B · higher than 83% of 726
- Revenue$23 M · higher than 51% of 647
- Net margin-790.2% · higher than 3% of 408
- Revenue growth-50.6% · higher than 18% of 438
- Price / sales99.4× · lower than 9% of 339
- Price / book3.8× · lower than 40% of 534
- FCF yield-5.7% · higher than 69% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V.🇳🇱 | $2.6 B | — | -790.2% | -50.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 21, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at NewAmsterdam Pharma Company N.V.? Verify and update this profile — free
Show NewAmsterdam Pharma Company N.V.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.